ziprasidone

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Medication Adherence

Conditions

Medication Adherence, Bipolar Disorder

Trial Timeline

Jan 1, 2011 → Aug 1, 2012

NCT ID

NCT01293825

About ziprasidone

ziprasidone is a approved stage product being developed by Pfizer for Medication Adherence. The current trial status is completed. This product is registered under clinical trial identifier NCT01293825. Target conditions include Medication Adherence, Bipolar Disorder.

What happened to similar drugs?

2 of 3 similar drugs in Medication Adherence were approved

Approved (2) Terminated (0) Active (1)

✅Advagraf + PrografAstellas PharmaApproved

🔄Tacrolimus BID + Advagraf QDAstellas PharmaPhase 3

✅TasP using ART regimen as per Benin guidelines + PrEP using TruvadaGilead SciencesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01157559	Approved	Completed	—	May 1, 2010	First Episode Psychosis
NCT02935998	Approved	UNKNOWN	Oct 1, 2016	Dec 1, 2017	Schizophrenia
NCT01293825	Approved	Completed	Jan 1, 2011	Aug 1, 2012	Medication Adherence
NCT01198353	Approved	Completed	Sep 1, 2010	Dec 1, 2013	Schizophrenia
NCT00579670	Pre-clinical	Completed	Oct 1, 2007	Apr 1, 2009	Schizophrenia
NCT00454883	Pre-clinical	Completed	Apr 1, 2007	Dec 1, 2007	Affective Psychosis, Bipolar
NCT00406315	Approved	Completed	Nov 1, 2006	Mar 1, 2009	Schizophrenia
NCT00421954	Phase 3	Completed	May 1, 2006	May 1, 2009	Schizophreniform Disorder
NCT01053429	Pre-clinical	Completed	Jun 1, 2005	Feb 1, 2010	Bipolar Disorder
NCT00458211	Approved	Completed	May 1, 2005	Apr 1, 2008	Schizophrenia
NCT00237666	Approved	Completed	Feb 1, 2005	Feb 1, 2008	Bipolar II Disorder
NCT00351000	Approved	Completed	Jan 1, 2005	Mar 1, 2007	Schizophrenia
NCT00137020	Approved	Completed	Nov 1, 2004	Apr 1, 2006	Schizophrenia
NCT00645229	Phase 3	Terminated	Sep 1, 2004	Mar 1, 2005	Schizophrenia
NCT00649064	Approved	Completed	Dec 1, 2003	Sep 1, 2004	Schizoaffective Disorder
NCT00650429	Approved	Completed	Oct 1, 2003	May 1, 2005	Schizophrenia
NCT00395031	Phase 2/3	Completed	Sep 1, 2003	Jan 1, 2010	Schizophrenia
NCT00645320	Approved	Completed	Aug 1, 2003	Aug 1, 2004	Pyschotic Disorders
NCT00644800	Approved	Completed	Jul 1, 2003	May 1, 2004	Schizophrenia
NCT00143351	Phase 3	Completed	Jun 1, 2003	Sep 1, 2005	Schizophrenia

Competing Products

6 competing products in Medication Adherence

See all competitors

Product	Company	Stage	Hype Score
DFN-11 Injection	Dr. Reddy's Laboratories	Phase 2	24
Advagraf + Prograf	Astellas Pharma	Approved	39
Tacrolimus BID + Advagraf QD	Astellas Pharma	Phase 3	36
Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + 0.9% natural saline	Johnson & Johnson	Pre-clinical	22
TasP using ART regimen as per Benin guidelines + PrEP using Truvada	Gilead Sciences	Approved	43
Levetiracetam	UCB	Phase 2	35